^
CANCER:

Hepatocellular Cancer

PIK3CA H1047R
HCC
palbociclib + alpelisib
Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
PIK3CA H1047R
HCC
alpelisib + TAK-228
Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
PIK3CA E545K
HCC
alpelisib
Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
PIK3CA H1047R
HCC
alpelisib
Resistant: D – Preclinical
Cell Death Dis - 2 weeks
No biomarker
HCC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
No biomarker
HCC
cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
HCC
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
AFP elevation
HCC
ramucirumab
Sensitive: A1 - Approval
No biomarker
HCC
regorafenib
Sensitive: A1 - Approval
No biomarker
HCC
lenvatinib
Sensitive: A1 - Approval
No biomarker
HCC
sorafenib
Sensitive: A1 - Approval
No biomarker
HCC
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
HCC
tislelizumab
Sensitive: A1 - Approval
No biomarker
HCC
nivolumab
Sensitive: A2 - Guideline
NTRK3 fusion
HCC
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
HCC
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
HCC
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
HCC
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
HCC
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
HCC
entrectinib
Sensitive: A2 - Guideline
No biomarker
HCC
sirolimus
Sensitive: A2 - Guideline
MSI-H/dMMR
HCC
dostarlimab
Sensitive: A2 - Guideline
NCCN - 4 weeks
AFP elevation
HCC
regorafenib
Sensitive: B - Late Trials
FGF21-H
HCC
lenvatinib
Sensitive: B - Late Trials
No biomarker
HCC
SRF388
Sensitive: B - Late Trials
HGF-H + VEGFA-H
HCC
erlotinib + sorafenib
Resistant: B - Late Trials
VEGFA-H
HCC
lenvatinib
Resistant: B - Late Trials
FGFR2 fusion
HCC
infigratinib
Sensitive: C1 - Off-label
PD-L1 expression
HCC
lenvatinib
Sensitive: C2 – Inclusion Criteria
AFP elevation
HCC
sorafenib + LY2157299
Sensitive: C2 – Inclusion Criteria
TSC2 overexpression
HCC
everolimus
Resistant: C3 – Early Trials
FOXA3 overexpression
HCC
sorafenib
Sensitive: C3 – Early Trials
CXCL12-H
HCC
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
KDR-H
HCC
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
VEGFA-H
HCC
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
ST6GAL1 elevation
HCC
lenvatinib
Sensitive: C3 – Early Trials
ARID1A mutation
HCC
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 expression
HCC
PD1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 expression
HCC
tislelizumab
Sensitive: C3 – Early Trials
GPC3 overexpression
HCC
atezolizumab + RG7686
Sensitive: C3 – Early Trials
AFP elevation
HCC
cabozantinib tablet
Sensitive: C3 – Early Trials
ANGPT2-H
HCC
sorafenib
Sensitive: C3 – Early Trials
FGF19-H
HCC
sorafenib
Sensitive: C3 – Early Trials
FGF19-L
HCC
lenvatinib
Sensitive: C3 – Early Trials
ANGPT2-L
HCC
lenvatinib
Sensitive: C3 – Early Trials
FGFR4 G388R + NOS3 rs2070744
HCC
lenvatinib
Sensitive: C3 – Early Trials
miR-216a-3p overexpression
HCC
sorafenib
Sensitive: C3 – Early Trials
HES1 overexpression
HCC
bevacizumab + atezolizumab
Resistant: C3 – Early Trials
Tregs-H
HCC
bevacizumab + atezolizumab
Sensitive: C3 – Early Trials
KDR overexpression
HCC
bevacizumab + atezolizumab
Sensitive: C3 – Early Trials
PAK4 deletion
HCC
Immunotherapy
Sensitive: C3 – Early Trials
CDKN2A deletion
HCC
Immunotherapy
Sensitive: C3 – Early Trials
Chr amplification(11)(q23)
HCC
Immunotherapy
Sensitive: C3 – Early Trials
HOXC8 overexpression
HCC
oxaliplatin
Sensitive: C3 – Early Trials
ATP5IF1 overexpression
HCC
sorafenib
Resistant: C3 – Early Trials
PI16 overexpression
HCC
sorafenib
Resistant: C3 – Early Trials
TGFB1 elevation
HCC
sorafenib + LY2157299
Sensitive: C3 – Early Trials
VEGFA elevation
HCC
sunitinib
Sensitive: C3 – Early Trials
KRAS G13D
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS Q61H
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS A146T
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS G12V
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS G12S
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS G12R
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS G12D
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS G12C
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS G12A
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
NRAS Q61R
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
NRAS Q61L
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
NRAS Q61K
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
NRAS Q61H
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
FGF19 positive
HCC
BLU-554
Sensitive: C3 – Early Trials
FGF19 negative
HCC
BLU-554
Resistant: C3 – Early Trials
FGF19 overexpression
HCC
BLU-554
Sensitive: C3 – Early Trials
FGF4 amplification
HCC
sorafenib
Sensitive: C3 – Early Trials
FGF3 amplification
HCC
sorafenib
Sensitive: C3 – Early Trials
ADAM9 underexpression
HCC
nivolumab
Sensitive: C3 – Early Trials
TGFB1-H
HCC
pembrolizumab
Sensitive: C3 – Early Trials
AFP elevation
HCC
sorafenib
Sensitive: C3 – Early Trials
CD133 overexpression
HCC
sorafenib
Resistant: C3 – Early Trials
THY1 overexpression
HCC
sorafenib
Resistant: C3 – Early Trials
EFNB2 negative
HCC
sEphB4-HSA
Sensitive: C3 – Early Trials
EFNB2 positive
HCC
sEphB4-HSA
Sensitive: C3 – Early Trials
PD-L1 expression
HCC
SNG-162
Sensitive: C3 – Early Trials
S100A16 overexpression
HCC
sorafenib
Resistant: C3 – Early Trials
S100A8 overexpression
HCC
sorafenib
Resistant: C3 – Early Trials
KPNA3 underexpression
HCC
sorafenib
Sensitive: C3 – Early Trials
PCSK9 underexpression
HCC
Immunotherapy
Sensitive: C3 – Early Trials
NFE2L2 overexpression
HCC
sorafenib
Resistant: C3 – Early Trials
MET overexpression
HCC
tepotinib
Sensitive: C3 – Early Trials
ASS1 negative
HCC
BCT-100
Sensitive: C3 – Early Trials
KMT2C mutation
HCC
PD1 inhibitor + lenvatinib
Sensitive: C3 – Early Trials
DDR
HCC
FOLFOX
Sensitive: C3 – Early Trials
GPC3 positive
HCC
CAR-T immunotherapy
Sensitive: C3 – Early Trials
FGF19 positive
HCC
H3B-6527
Sensitive: C3 – Early Trials
ANGPT2-L
HCC
pembrolizumab + lenvatinib
Sensitive: C3 – Early Trials